SAB Biotherapeutics (SABS) PT Raised to $14 at Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell raised the price target on SAB Biotherapeutics (NASDAQ: SABS) to $14.00 (from $12.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
